Haryana sends syrup samples to Kolkata lab after WHO flags Sonipat firm

Samples of four cough syrups made by a Sonipat-based firm have been sent to the Central Drugs Laboratory in Kolkata for examination, Haryana's Health Minister Anil Vij said

cough syrup, medicine, cold
File photo of cough syrup. Photo: Shutterstock
Press Trust of India Chandigarh
2 min read Last Updated : Oct 06 2022 | 4:59 PM IST

Samples of four cough syrups manufactured by a Sonipat-based firm have been sent to the Central Drugs Laboratory in Kolkata for examination, Haryana's Health Minister Anil Vij said Thursday, a day after the WHO potentially linked them to the deaths of 66 children in The Gambia.

The World Health Organization (WHO) on Wednesday warned that four "contaminated" and "substandard" cough syrups allegedly produced by Maiden Pharmaceuticals Limited based in Haryana's Sonepat could be the reason for the deaths of children in the West African nation.

A probe has already been initiated by India's drug regulator, the Drugs Controller General of India.

"The samples have been collected by a team of the DCGA and Haryana's Food and Drugs Administration Department and sent to the CDL, Kolkata for examination," Vij told PTI over phone on Thursday.

He said a senior official of Centre's Department of Pharmaceuticals spoke with Haryana's Additional Chief Secretary (Health).

Vij said the cough syrups manufactured by the pharma company were approved for export. "It is not available for sale or marketing in the country."

"Whatever action has to be taken will be taken once the CDL report comes. Only after the report is in, we can arrive at any conclusion," Vij said.

When asked about the matter at a news conference here, Haryana Chief Minister Manohar Lal Khattar said the Centre was looking into this issue.

When an international issue in involved, the Government of India deals with it and they are dealing with it, he said.

However, he added, "So far, we do not have information on whether the deaths happened actually because of these medicines or due to some other reasons.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :World Health OrganizationHaryanahealth news

First Published: Oct 06 2022 | 4:59 PM IST

Next Story